1. Pharmacokinetics & Pharmacodynamics: absorption, distribution, metabolism,
excretion, bioavailability, first-pass effect, half-life, volume of distribution,
clearance, therapeutic index, receptor agonism/antagonism, potency vs
efficacy, P-glycoprotein, prodrugs, pharmacogenomics 1 2 3
2. Cellular Adaptation, Injury & Genetics: hypertrophy, hyperplasia, atrophy,
metaplasia, dysplasia, apoptosis vs necrosis, hypoxic injury, inflammation
mediators, hypersensitivity types, genetic inheritance patterns, chromosomal
disorders 4 9
3. Cardiovascular & Renal Pharmacology: RAAS inhibitors, beta-blockers, calcium
channel blockers, diuretics, heart failure agents (sacubitril/valsartan, SGLT2
inhibitors), antiarrhythmics, anticoagulants, dyslipidemia management, acute
kidney injury, chronic kidney disease medication adjustments 1 5 7
4. Endocrine, Respiratory & GI Pharmacology: diabetes medications (insulin,
metformin, SGLT2 inhibitors, GLP-1 agonists), thyroid disorders, corticosteroid
therapy, asthma/COPD inhalers, acid-suppressive agents, IBD therapies,
hepatitis pharmacotherapy 1 3
5. CNS & Psychopharmacology: antidepressants (SSRIs, SNRIs), antipsychotics,
mood stabilizers (lithium), anxiolytics, antiseizure medications, Parkinson
disease agents, Alzheimer disease therapies, opioid and non-opioid analgesics
1 7
6. Anti-Infectives & Antimicrobial Stewardship: aminoglycosides, beta-lactams,
fluoroquinolones, vancomycin, antifungals, antivirals, antibiotic resistance
mechanisms, culture-guided therapy, prophylactic antimicrobials 1 2
, 7. Immunology & Immunosuppression: transplant immunosuppressants, biologic
agents, vaccine pharmacology, immunoglobulins, autoimmune disease
therapies, hypersensitivity reactions to drugs 1
8. Hematologic Pharmacology: anticoagulants (warfarin, DOACs, heparin),
antiplatelets, thrombolytics, anemia management (iron, erythropoietin), colony-
stimulating factors, transfusion reactions 3 7
9. Special Populations & Pharmacogenomics: pregnancy/lactation drug safety,
pediatric dosing, geriatric polypharmacy, hepatic/renal dose adjustments,
CYP450 polymorphisms, HLA allele screening 1 3 5
10. Adverse Drug Reactions & Drug Interactions: Type A vs Type B reactions,
CYP450-mediated interactions, protein-binding displacement,
additive/synergistic toxicity, black box warnings, monitoring parameters 2 3 7
WGU D027 Exam Advanced Pathopharmacological Foundations
1. A patient with decreased hepatic function is at greatest risk for prolonged drug
effects from which pharmacokinetic alteration?
A. Increased renal filtration rate
B. Impaired first-pass metabolism and reduced clearance
C. Enhanced distribution into adipose tissue
D. Accelerated gastrointestinal absorption
Correct Answer: B
Rationale: The liver is the primary site of drug metabolism; hepatic impairment
,reduces first-pass metabolism and systemic clearance, prolonging half-life and
increasing toxicity risk . 2
2. Which statement most accurately describes the clinical significance of a drug
with a narrow therapeutic index?
A. It requires minimal monitoring because toxicity is rare
B. Small changes in plasma concentration can produce therapeutic failure or
toxicity
C. It always requires intravenous administration
D. It has no significant drug interactions
Correct Answer: B
Rationale: A narrow therapeutic index means the range between effective and
toxic concentrations is small, requiring careful dosing and therapeutic drug
monitoring . 3
3. A patient with renal failure requires dosage adjustment primarily for which
category of medications?
A. Drugs extensively metabolized by the liver before reaching systemic
circulation
B. Drugs excreted unchanged by the kidneys
C. Topical corticosteroids applied to intact skin
D. Sublingual nitroglycerin formulations
Correct Answer: B
Rationale: Drugs cleared unchanged through the kidneys accumulate when renal
, function declines, necessitating dose reduction . 2
4. Which receptor activity best characterizes a partial agonist?
A. Produces no effect when binding to a receptor
B. Produces the same maximal effect as a full agonist
C. Produces a smaller maximal response even when all receptors are occupied
D. Completely blocks receptor activation by endogenous ligands
Correct Answer: C
Rationale: Partial agonists bind and activate receptors but produce less than
maximal response regardless of dose . 2
5. A patient taking warfarin is prescribed trimethoprim-sulfamethoxazole for a
urinary tract infection. Which interaction mechanism best explains the
anticipated INR rise?
A. CYP2C9 inhibition plus protein-binding displacement of warfarin
B. Increased renal excretion of warfarin metabolites
C. Induction of vitamin K production by gut flora
D. Enhanced warfarin absorption from the gastrointestinal tract
Correct Answer: A
Rationale: TMP-SMX inhibits CYP2C9 (reducing S-warfarin metabolism) and
displaces warfarin from albumin, potentiating anticoagulation . 7
6. Which mechanism best explains the combined therapeutic benefit of
sacubitril/valsartan in heart failure with reduced ejection fraction?
excretion, bioavailability, first-pass effect, half-life, volume of distribution,
clearance, therapeutic index, receptor agonism/antagonism, potency vs
efficacy, P-glycoprotein, prodrugs, pharmacogenomics 1 2 3
2. Cellular Adaptation, Injury & Genetics: hypertrophy, hyperplasia, atrophy,
metaplasia, dysplasia, apoptosis vs necrosis, hypoxic injury, inflammation
mediators, hypersensitivity types, genetic inheritance patterns, chromosomal
disorders 4 9
3. Cardiovascular & Renal Pharmacology: RAAS inhibitors, beta-blockers, calcium
channel blockers, diuretics, heart failure agents (sacubitril/valsartan, SGLT2
inhibitors), antiarrhythmics, anticoagulants, dyslipidemia management, acute
kidney injury, chronic kidney disease medication adjustments 1 5 7
4. Endocrine, Respiratory & GI Pharmacology: diabetes medications (insulin,
metformin, SGLT2 inhibitors, GLP-1 agonists), thyroid disorders, corticosteroid
therapy, asthma/COPD inhalers, acid-suppressive agents, IBD therapies,
hepatitis pharmacotherapy 1 3
5. CNS & Psychopharmacology: antidepressants (SSRIs, SNRIs), antipsychotics,
mood stabilizers (lithium), anxiolytics, antiseizure medications, Parkinson
disease agents, Alzheimer disease therapies, opioid and non-opioid analgesics
1 7
6. Anti-Infectives & Antimicrobial Stewardship: aminoglycosides, beta-lactams,
fluoroquinolones, vancomycin, antifungals, antivirals, antibiotic resistance
mechanisms, culture-guided therapy, prophylactic antimicrobials 1 2
, 7. Immunology & Immunosuppression: transplant immunosuppressants, biologic
agents, vaccine pharmacology, immunoglobulins, autoimmune disease
therapies, hypersensitivity reactions to drugs 1
8. Hematologic Pharmacology: anticoagulants (warfarin, DOACs, heparin),
antiplatelets, thrombolytics, anemia management (iron, erythropoietin), colony-
stimulating factors, transfusion reactions 3 7
9. Special Populations & Pharmacogenomics: pregnancy/lactation drug safety,
pediatric dosing, geriatric polypharmacy, hepatic/renal dose adjustments,
CYP450 polymorphisms, HLA allele screening 1 3 5
10. Adverse Drug Reactions & Drug Interactions: Type A vs Type B reactions,
CYP450-mediated interactions, protein-binding displacement,
additive/synergistic toxicity, black box warnings, monitoring parameters 2 3 7
WGU D027 Exam Advanced Pathopharmacological Foundations
1. A patient with decreased hepatic function is at greatest risk for prolonged drug
effects from which pharmacokinetic alteration?
A. Increased renal filtration rate
B. Impaired first-pass metabolism and reduced clearance
C. Enhanced distribution into adipose tissue
D. Accelerated gastrointestinal absorption
Correct Answer: B
Rationale: The liver is the primary site of drug metabolism; hepatic impairment
,reduces first-pass metabolism and systemic clearance, prolonging half-life and
increasing toxicity risk . 2
2. Which statement most accurately describes the clinical significance of a drug
with a narrow therapeutic index?
A. It requires minimal monitoring because toxicity is rare
B. Small changes in plasma concentration can produce therapeutic failure or
toxicity
C. It always requires intravenous administration
D. It has no significant drug interactions
Correct Answer: B
Rationale: A narrow therapeutic index means the range between effective and
toxic concentrations is small, requiring careful dosing and therapeutic drug
monitoring . 3
3. A patient with renal failure requires dosage adjustment primarily for which
category of medications?
A. Drugs extensively metabolized by the liver before reaching systemic
circulation
B. Drugs excreted unchanged by the kidneys
C. Topical corticosteroids applied to intact skin
D. Sublingual nitroglycerin formulations
Correct Answer: B
Rationale: Drugs cleared unchanged through the kidneys accumulate when renal
, function declines, necessitating dose reduction . 2
4. Which receptor activity best characterizes a partial agonist?
A. Produces no effect when binding to a receptor
B. Produces the same maximal effect as a full agonist
C. Produces a smaller maximal response even when all receptors are occupied
D. Completely blocks receptor activation by endogenous ligands
Correct Answer: C
Rationale: Partial agonists bind and activate receptors but produce less than
maximal response regardless of dose . 2
5. A patient taking warfarin is prescribed trimethoprim-sulfamethoxazole for a
urinary tract infection. Which interaction mechanism best explains the
anticipated INR rise?
A. CYP2C9 inhibition plus protein-binding displacement of warfarin
B. Increased renal excretion of warfarin metabolites
C. Induction of vitamin K production by gut flora
D. Enhanced warfarin absorption from the gastrointestinal tract
Correct Answer: A
Rationale: TMP-SMX inhibits CYP2C9 (reducing S-warfarin metabolism) and
displaces warfarin from albumin, potentiating anticoagulation . 7
6. Which mechanism best explains the combined therapeutic benefit of
sacubitril/valsartan in heart failure with reduced ejection fraction?
